Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discovery and Optimization of a STING Agonist Platform for Application in Antibody Drug Conjugates.
Duvall JR, Thomas JD, Bukhalid RA, Catcott KC, Bentley KW, Collins SD, Eitas T, Jones BD, Kelleher EW, Lancaster K, Protopopova M, Ray SS, Ter-Ovanesyan E, Xu L, Yang L, Zurita J, Damelin M, Toader D, Lowinger TB. Duvall JR, et al. Among authors: ter ovanesyan e. J Med Chem. 2023 Aug 10;66(15):10715-10733. doi: 10.1021/acs.jmedchem.3c00907. Epub 2023 Jul 24. J Med Chem. 2023. PMID: 37486969 Free PMC article.
Dolaflexin: A Novel Antibody-Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect.
Yurkovetskiy AV, Bodyak ND, Yin M, Thomas JD, Clardy SM, Conlon PR, Stevenson CA, Uttard A, Qin L, Gumerov DR, Ter-Ovanesyan E, Bu C, Johnson AJ, Gurijala VR, McGillicuddy D, DeVit MJ, Poling LL, Protopopova M, Xu L, Zhang Q, Park PU, Bergstrom DA, Lowinger TB. Yurkovetskiy AV, et al. Among authors: ter ovanesyan e. Mol Cancer Ther. 2021 May;20(5):885-895. doi: 10.1158/1535-7163.MCT-20-0166. Epub 2021 Mar 15. Mol Cancer Ther. 2021. PMID: 33722857
The Dolaflexin-based Antibody-Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b.
Bodyak ND, Mosher R, Yurkovetskiy AV, Yin M, Bu C, Conlon PR, Demady DR, DeVit MJ, Gumerov DR, Gurijala VR, Lee W, McGillicuddy D, Park PU, Poling LL, Protopova M, Qin L, Stevenson CA, Ter-Ovanesyan E, Uttard A, Xiao D, Xu J, Xu L, Bergstrom DA, Lowinger TB. Bodyak ND, et al. Among authors: ter ovanesyan e. Mol Cancer Ther. 2021 May;20(5):896-905. doi: 10.1158/1535-7163.MCT-20-0183. Epub 2021 Mar 15. Mol Cancer Ther. 2021. PMID: 33722858
Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer.
Toader D, Fessler SP, Collins SD, Conlon PR, Bollu R, Catcott KC, Chin CN, Dirksen A, Du B, Duvall JR, Higgins S, Kozytska MV, Bellovoda K, Faircloth C, Lee D, Li F, Qin L, Routhier C, Shaw P, Stevenson CA, Wang J, Wongthida P, Ter-Ovanesyan E, Ditty E, Bradley SP, Xu L, Yin M, Yurkovetskiy AV, Mosher R, Damelin M, Lowinger TB. Toader D, et al. Among authors: ter ovanesyan e. Mol Cancer Ther. 2023 Sep 5;22(9):999-1012. doi: 10.1158/1535-7163.MCT-22-0786. Mol Cancer Ther. 2023. PMID: 37294948 Free PMC article. Clinical Trial.
Development of a Novel DNA Mono-alkylator Platform for Antibody-Drug Conjugates.
Thomas JD, Yurkovetskiy AV, Yin M, Bodyak ND, Tang S, Protopopova M, Kelleher E, Jones B, Yang L, Custar D, Catcott KC, Demady DR, Collins SD, Xu L, Bu C, Qin L, Ter-Ovanesyan E, Damelin M, Toader D, Lowinger TB. Thomas JD, et al. Among authors: ter ovanesyan e. Mol Cancer Ther. 2024 Apr 2;23(4):541-551. doi: 10.1158/1535-7163.MCT-23-0622. Mol Cancer Ther. 2024. PMID: 38354416
13 results